High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern
artículo original

View/ Open
Date
2021Author
Moreira Soto, Andrés
Gutiérrez, José María
Alape Girón, Alberto
Drexler, Jan Felix
Arguedas Gómez, Mauricio
Brenes Porras, Hebleen
Buján Boza, Willem Aart
Corrales Aguilar, Eugenia
Díaz Oreiro, Cecilia
Echeverri McCandless, Ann
Flores Díaz, Marietta
Macaya Hayes, Román
Kühne, Arne
Molina Mora, José Arturo
Mora Rodríguez, Javier Francisco
Sanabria Castro, Alfredo
Sánchez Brenes, Andrés
Sánchez Céspedes, Laura Vanessa
Segura Ruiz, Álvaro
Segura Agüero, Eduardo
Solano Centeno, Daniela
Soto Garita, Claudio
Stynoski, Jennifer Lynn
Vargas Arroyo, Mariángela
Villalta Arrieta, Mauren
Reusken, Chantal B. E. M.
Drosten, Christian
Metadata
Show full item recordAbstract
SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and
therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We
tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical
trials in Costa Rica against five globally circulating variants of concern: alpha, beta,
epsilon, gamma and delta, using plaque reduction neutralization assays. We show that
equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations
in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations
when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad
coverage, low-cost and a scalable COVID-19 treatment.
External link to the item
10.3389/fmed.2021.735853Collections
- Microbiología [1105]